Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects

This will be a single dose, randomised, open label, parallel group study conducted in the US
to examine the Pharmacokinetics (PK), Pharmacodynamics (PD), safety, and tolerability of
ticagrelor in end stage renal disease (ESRD) subjects on hemodialysis (HD) compared with
healthy subjects with normal renal function. Up to a total of 30 male and female adult
subjects aged 18 to 80 years (inclusive) with a weight of at least 50 kg and a body mass
index between 18 and 40 kg/m2 (inclusive), will be dosed to assure that there will be 20
evaluable subjects (10 subjects on HD and in 10 healthy subjects with normal renal function
(CrCL ≥90 mL/min). The normal renal function groups should have a similar distribution with
respect to age, weight and gender. Subjects will be required to have an inpatient stay from
the day prior to dosing until the 48-hour post-dose time-point to ensure that all PK samples
are collected at the appropriate timepoints. The study will be conducted in two groups: Group
A consisting of ESRD subjects on HD, Group B consisting of healthy subjects. A crossover
design will be implemented for Group A subjects as follows: Group A subjects will be
randomized into two sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will
receive treatment A in Period 1 and treatment B in Period 2. There will be washout period of
at least 7 days between Period 1 and Period 2 in Sequence 1. Similarly in Sequence 2,
subjects will receive treatment B in Period 1 and treatment A in Period 2. There will be a
washout period of at least 7 days between Period 1 and Period 2 in Sequence 2 as well.
Treatment A and treatment B are defined as follows: Treatment A: subjects will be dosed with
an oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the
next dialysis session; • Treatment B: subjects will be dosed with an oral 90 mg ticagrelor
tablet just prior to dialysis session.(NB: Treatment B dosing should occur within 5 minutes
of dialysis start). Group B subjects (healthy subjects) with normal renal function (CrCL of ≥
90 mL/min) will receive just an oral 90 mg ticagrelor referred to as treatment H. All doses
will be administered in an open-label design.

Inclusion Criteria:

- Male or Female aged 18 to 80 years (inclusive).

- Normal renal function (CrCl of ≥90 mL/min) or End Stage Renal Disease (ESRD) requiring
hemodialysis.

Exclusion Criteria:

- Any indication for oral anticoagulant or anti platelet treatment during study period.
Must be off treatment for at least 3 weeks (low dose 81mg aspirin is allowed for
hemodialysis subjects only).

- Acute Coronary Syndrome (ACS) within past 12 months.

- Contraindications to ticagrelor (ie: active pathological bleeding, severe hepatic
impairment, history of hemorrhagic stroke, allergic to ticagrelor).

- Platelet count <100000/μL, hemoglobin <9g/dL

- Blood donation within 90 days of dosing

- Risk for bradycardia

- Investigational drug within 30 days or 6 half-lives, whichever is longer, before
dosing

- Concomitant therapy with CYP3A inhibitors/substrates with narrow therapeutic index,or
strong CYP3A inducers 14 days before dosing until completion of the follow-up visit.

- History of alcohol, drug, or substance abuse within the past year

- Clinically significant laboratory abnormalities as judged by the investigator.

- Increased bleeding risk including GI bleeding in past 30 days; history of
intracranial, retroperitoneal, or spinal bleeding, recent major trauma within 30 days
of dosing, Sustained uncontrolled hypertension, history of hemorrhagic disorders.

- Pregnant or lactating females, or females of child-bearing potential (ie, those who
are not chemically or surgically sterilised or who are not post-menopause) who are not
willing to use a medically accepted method of contraception that is considered
reliable in the judgment of the investigator throughout the duration of the study OR
females who have a positive pregnancy test at Visit 1.